Event Overview
Oligonucleotide therapeutics have gained recent popularity given their vast applications in genetic disorders, cancers, and infectious diseases. There are many challenges when developing bioanalytical methods for the quantitation of oligonucleotides, including stability, recovery, non-specific binding, chromatographic retention, and ionization. In this webinar, case studies with various oligonucleotide structures will be presented along with strategies for overcoming bioanalytical challenges.
Key Learning Objectives:
- Best practices for oligonucleotide sample preparation
- Strategies to ensure the best setup for chromatography and ionization
- How to reach good quantitative performance using innovative analytical tools
Who Should View:
- Senior Scientist/Group Leader
- Lab Manager
- Principal Investigator
- Scientist
- Lab Technician
What You Need to Know:
Format: On demand
Duration: 37 minutes
Presenter:
 | Rathna Veeramachaneni, PhD Director, Biopharma LC-MS/MS, KCAS Bio (KS, USA) Rathna J. Veeramachaneni is currently the Director of Biopharma LC-MS/MS at KCAS Bio. Rathna’s prior experience included working in the pharmaceutical and CRO space, developing quantitative methods for small and large molecule therapeutics and biomarkers. Rathna received her PhD from Duquesne University (PA, USA), working on crosslinking combined with proteomic mass spectrometry for identification of structural conformational changes in membrane ion channels. Rathna has worked on many different biopharmaceutical modalities such as oligonucleotides (antibody-oligonucleotide conjugates, duplexes, and antisense oligonucleotides), monoclonal antibodies, antibody-drug conjugates, fusion and chimeric proteins, as well as biomarkers for both small and large molecules, including glycosphingolipids and eicosanoids. Rathna has significant expertise in hybrid LC–MS/MS, both at the protein and peptide level, along with more traditional LC–MS/MS assays utilizing protein precipitation, digestions, and SPE approaches. Her therapeutic area of expertise includes indications of cancer, inflammation, neurodegenerative diseases, and rare diseases. Rathna is passionate about using the best science to help drive and support the drug development process, and advocates customized strategic approaches by incorporating notable advancements in the ever-growing field to find creative solutions that are better, faster, and/or more efficient. |
